Retifanlimab in Merkel cell carcinoma

Kari Kendra, MD, PhD, The Ohio State University, Columbus, OH, describes the impact of the recent FDA approval of retifanlimab for metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). MCC has traditionally been very responsive to immunotherapies, and retifanlimab will provide an additional treatment option for this group of patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.